Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 5.12%
As of Wednesday, July 22, Dyne Therapeutics, Inc.’s DYN share price has dipped by 5.12%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Commentary & Analysis
Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 5.13%
As of Thursday, July 16, Dyne Therapeutics, Inc.’s DYN share price has dipped by 5.13%, which has investors questioning if this is right time to buy.Michael Rose
Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 5.11%
As of Friday, July 10, Dyne Therapeutics, Inc.’s DYN share price has dipped by 5.11%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Down 5.41%
As of Wednesday, July 08, Dyne Therapeutics, Inc.’s DYN share price has dipped by 5.41%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Dyne Therapeutics, Inc.’s (DYN) Stock Is Up 5.50%
As of Tuesday, June 30, Dyne Therapeutics, Inc.’s DYN share price has surged by 5.50%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | DYN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4,853.5 | $286.3 | 66% |
|
| Shares Out (Mil) | 165.5 | 54.2 | 73% |
|
| Institutional Ownership | 99.8% | 92.8% | 94% |
|
| Float (Mil) | 186.3 | 39.7 | 73% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 1,844 | 534 | 81% |
|
| Price Change (52-week) |
112.2% | 58.7% | 92% |
|
| Growth | DYN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (49.7%) | (10.1%) | 7% |
|
| EPS (5yr) | 3.4% | 16.0% | 36 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (29.2%) | (15.6%) | 20% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 13 | 13 | |
| Current EPS | ($0.878) | ($3.569) | ($3.341) | |
| Month Ago EPS | ($0.765) | ($3.068) | ($2.938) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.757) | ($3.077) | ($3.008) | |
| Year/Year Chg | (18.6%) | 2.7% | (25.3%) | |
| Financials | DYN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($519) | ($43) | 3% |
|
| EPS (TTM) | ($3.349) | ($1.400) | 10% |
|
| Operating Cash Flow (TTM) (Mil) | ($478) | ($31) | 2% |
|
| Net Cash Flow (TTM) (Mil) | $192 | $2 | 84% |
|
| Long-Term Debt (Q1) (Mil) | $214 | $4 | 50% |
|
| Enterprise Value (Q1) (Mil) | na | $160 | na |
|
| Valuation | DYN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.13 | 2.77 | 82% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DYN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (60.3%) | (47.3%) | 10% |
|
| ROE | (81.6%) | (55.0%) | 11% |
|
| Liabilities to Assets | 29.4% | 29.6% | 21% |
|
| F-Score | 1 | 2 | 1% |
|
Passing Stock Screens
As of 8/19/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Est Rev: Lowest 30 Down
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.9% |
| +/- S&P 500: | -4.6 |
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.4% |
| +/- S&P 500: | -5.1 |
